Skip Navigation
Menu
Position Papers |1 April 1997

CLINICAL GUIDELINE: PART I: Guidelines for Risk Stratification after Myocardial Infarction

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
Copyright ©2004 by the American College of Physicians
2004
  • American College of Physicians* *This paper, written by Eric D. Peterson, MD, Leslee J. Shaw, PhD, and Robert M. Califf, MD, was developed for the Health and Public Policy Committee by the Clinical Efficacy Assessment Subcommittee: George E. Thibault, MD, Chair; John R. Feussner, MD, Co-Chair; Anne-Marie J. Audet, MD; Gottlieb C. Friesinger Jr., MD; Daniel L. Kent, MD; Keith I. Marton, MD; Valerie Anne Palda, MD; John J. Whyte, MD; and Preston L. Winters, MD. This paper was approved by the Board of Regents on 22 April 1996. Note: The Clinical Efficacy Assessment Project (CEAP) of the American College of Physicians is designed to evaluate and inform College members and others about the safety and efficacy of diagnostic and therapeutic methods. Acknowledgment: The authors thank Patricia Williams for editorial assistance. Requests for Reprints: Customer Service Representative, American College of Physicians, Independence Mall West, Sixth Street at Race, Philadelphia, PA 19106-1572.
×
FULL TEXT
The numbers in square brackets are cross-references to the numbered sections in the accompanying background paper, “Risk Stratification after Myocardial Infarction,” which is part II of this Guideline (see pages 561-582).
In the 6 years since the publication of the previous American College of Physicians guidelines on risk stratification after myocardial infarction [1], the management of patients who have myocardial infarction has changed dramatically. Three major factors have prompted this change: the increased availability of empirical data from randomized clinical trials, the proliferation of diagnostic and interventional technologies, and the growth of managed care organizations.
The recent completion of...
FULL TEXT
PDF
Not Available
Citations
Citation

CLINICAL GUIDELINE: PART I: Guidelines for Risk Stratification after Myocardial Infarction. Ann Intern Med. 1997;126:556–560. doi: 10.7326/0003-4819-126-7-199704010-00011

Download citation file:

© 2019

×
Permissions

Published: Ann Intern Med. 1997;126(7):556-560.

DOI: 10.7326/0003-4819-126-7-199704010-00011

0 Citations

Related Articles
Clinical Guideline: Part II: Risk Stratification after Myocardial Infarction
Annals of Internal Medicine; 126 (7): 561-582
The Discrepancy between Observational Studies and Randomized Trials of Menopausal Hormone Therapy: Did Expectations Shape Experience?
Annals of Internal Medicine; 139 (11): 923-929
Incremental Value of the Leukocyte Differential and the Rapid Creatine Kinase-MB Isoenzyme for the Early Diagnosis of Myocardial Infarction
Annals of Internal Medicine; 122 (5): 335-341
The Role of Risk Stratification in the Early Management of a Myocardial Infarction
Annals of Internal Medicine; 116 (3): 223-237
View MoreView Less

Journal Club
Late thrombectomy reduced disability in acute stroke with mismatched clinical deficit and infarction volume
Annals of Internal Medicine; 168 (4): JC17
Review: Strategies to improve provider adoption and implementation of clinical practice guidelines were assessed
Annals of Internal Medicine; 166 (10): JC58
Review: β-blockers do not reduce mortality in myocardial infarction in the reperfusion era
Annals of Internal Medicine; 162 (6): JC3
Review: In high-risk patients, fatty acid supplementation does not prevent coronary events
Annals of Internal Medicine; 161 (6): JC7
View MoreView Less

Related Topics
Acute Coronary Syndromes
Cardiology
Coronary Heart Disease
Emergency Medicine

Acute Coronary Syndromes, Cardiology, Coronary Heart Disease, Emergency Medicine.

PubMed Articles
Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial.
Am Heart J 2019;
Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod.
J Neurol Sci 2019;
View More

Results provided by: PubMed

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×